Uses for thyroid hormone compounds or thyroid hormone-like compounds

• US 6,221,911 B1
• Filed: 03/09/1998
• Issued: 04/24/2001
• Est. Priority Date: 06/07/1995
• Status: Expired due to Term

• Current Assignee: Catherine Koo
• Original Assignee: Karo Pharma AB
• Inventors: Vahlquist, Anders B., Lavin, Thomas N.
• Primary Examiner(s): Jordan, Kimberly
• Application Number:
  US08/973,627
• Time in Patent Office: 1,142 Days
• Field of Search: 514/567, 514/859, 514/863
• US Class Current: 514/567
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/055 the aromatic ring being substituted by halogen
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/341 not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 31/425 Thiazoles
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/53 having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine melarsoprol A61K31/555 ; with four nitrogen atoms A61K31/495
• CPC Class Codes: A61K 8/44 Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
• CPC Class Codes: A61K 8/64 Proteins; Peptides; Derivatives or degradation products thereof
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 5/12 for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: A61Q 19/004 Aftersun preparations
• CPC Class Codes: A61Q 19/06 for countering cellulitis
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations

Abstract

This invention relates to the use of topically applied thyroid hormone compounds and thyroid hormone-like compounds which are receptor binding ligands, either agonists or antagonists, to improve the appearance of the skin and underlying subcutaneous fat and improve certain medical conditions when applied topically. These compounds can be used to treat skin conditions such as stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged kin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, corticosteroid atrophy, collagen deficient skin, and to diminish the size and improve the appearance of skin scarring from surgical or naturally occurring wounds, and to reduce the incidence of hyperkeratotic scarring. The thyroid agonists and antagonists may also promote differentiation and amelioration of dedifferentiated skin in premalignant lesions. The thyroid agonists and antagonists can be active in all organisms which contain the thyroid hormone receptors, notably amphibians, birds and subjects. Combination with Vitamin D analogs, glucocorticoids, and retinoids will potentiate and modify the effects of the thyroid hormones for increased benefit. Side effects of thyroid hormones which occur when the hormone is given orally and prevent usefulness for the above conditions are prevented when the hormone is topically applied.

Claims

1. A skin treatment composition for topical application, the composition comprising at least one thyroid hormone compound or thyroid hormone-like compound together with a pharmacologically acceptable base, wherein said thyroid hormone compound or thyroid hormone-like compound is a chemical entity which binds to TR-α

or TR-β

with an equilibrium dissociation constant, K_d, lower than 1 μ

M, wherein

2. A skin treatment composition according to claim 1, wherein said at least one thyroid hormone compound or said thyroid hormone-like compound is selected from the group consisting of Tri-iodothyronine (3,5,3′

-triiodothyronine, T3);

D and L thyroxine (T4);

3,3′

5′

tri-iodothyronine (reverse T3);

3,3′

-diiodothyronine;

T3 and T4 analogues such as 3,5,3′

,-Triiodo-L-thyronine methyl ester;

3,5,3′

-Triodo-L-thyronine hydrochloride;

L-thyroxine hydrochloride;

Tetrac (3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]acetic acid);

Triac ([4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]acetic acid);

Tetraprop;

Triprop ([4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propionic acid);

T4Bu;

T3Bu;

Thyroxamine;

Triiodothyronamine;

(5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyrimidin-5-yl)-methanol;

Benzyloxy-2-methoxyphenyl)-(6-methylpyridin-3-yl)methanol;

(5-Benzyloxy-2-methoxyphenyl)-(5-bromo-2-methoxypyridin-4-yl)methanol;

(5-benzyloxy-2-methoxyphenyl)-(2,6-difluoropyridin-3-yl)methanol;

(5-Benzyloxy-2-methoxyphenyl)-(2-methoxypyridin-4-yl)methanol;

4-Methoxy-3-[(2-methoxypyrimidin-5-yl)methyl]phenol;

4-Methoxy-3-[(6-methylpyrid-3-yl)methyl]phenol;

5-Benzyloxy-2-methoxybenzyl Bromide;

(5-Benzyloxy-2-methoxyphenyl-(6-chloropyridazin-3-yl)-acetonitrile;

4-Benzyloxy-2-[2-methoxythiazol-5-yl)methyl]anisole;

6-[(5-Hydroxy-2-methoxyphenyl)methyl]thiazol-2-(3H);

3′

-Heteroarylmethyl-4′

-)-methyl-3,5-dinitro-N-trifluoro-acetyl-L-thyronine Ethyl Esters;

3′

-heteroarylmethyl-3,5-di-iodo-4′

)-methyl-N-trifluoro-acetyl-L-thyronine Ethyl Esters;

3′

-heteroarylmethyl analogues of 3,3′

,5-tri-iodo-L-thyronine (T3);

3′

-substituted derivatives of the thyroid hormone 3,3′

5-triiodo-L-thyronine (T3);

L-3,3′

-T2;

DL-Br2I;

L-Br2iPr;

L-Me2I;

L-Me3;

L-Me4;

L-Me2IPr;

DL-IMeI;

L-3,5-Dimethyl-3′

-isopropylthyronine (DIMIT);

DL-BPT4;

B-triac;

BP-tetrac;

DL-SBT3;

DL-SBT4;

DL-MBT3;

MB-tetrac;

T2F;

T2Cl;

T2Br;

T2Me;

T2Et;

T2iPr;

T2nPr;

T2sBu;

T2tBu;

T2iBu;

T2Phe;

T2F2;

T2Cl2;

T2Me2;

3,5,3′

-Triiodo-D-thyronine;

3,5-Diiodo-4-hydroxyphenylpropionic acid (DIHPA);

Aryloxamic acids;

(arylamino)acetic acids;

arylpropionic acids;

arylthioacetic acids;

(aryloxy)acetic acid;

3,3′

-T2;

3,5-T2;

3′

,5′

-T2;

α

-methyl-3,5,3′

-triiodothyroacetic acid, α

-methyl-3,5,3′

-triiodothyropropionic acid, and α

-methyl-3,5,3′

,5′

-tetraiodothyropropionic acid;

methylene- and carbonyl-bridged analogs of iodinated thyronines or thyroacetic acids or iodinated benzofurans;

3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride;

[2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylaminoethoxy)-benzoyl)benzofuran hydrochloride;

] 2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran;

2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran;

2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran;

] 4′

-hydroxy-3′

-iodo-3,5 diiodo-4-(2-N,N-dimethylamino-(ethoxy)benzophenone hydrochloride;

2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzfuran;

4′

,4-dihydroxy 3′

3,5-triiodo-diphenylmethane;

[3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride;

2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylaminoethoxy)-benzoyl)benzofuran hydrochloride;

2-n-butyl-3-(3,5-diiodo-4-carboxymethoxy-benzoyl)benzofuran;

2-methyl-3-(3,5-diiodo-4-hydroxy-benzoyl)benzofuran;

2-methyl-3-(3,5-diiodo-4-carboxymethoxy-benzyl)benzofuran;

4′

-hydroxy-3′

-iodo-3,5-diiodo-4-(2-N,N-dimethylamino-ethoxy)benzophenone hydrochloride;

2-butyl-3-(3-iodo-4-hydroxybenzoyl)benzofuran;

4′

,4-dihydroxy-3′

3,5-triiodo-diphenylmethane;

] 3,5-diethyl,3′

-isopropyl thyronine (DIET); and

IpTA2 (3,5 diiodo-3′

isopropyl thyroacetic acid) and pharmacologically acceptable salts and derivatives thereof.

3. A composition according to claim 1 comprising a concentration of 5×

10⁸ times K_d or less of the said at least one thyroid hormone compound or said thyroid hormone-like compound.

4. A composition according to claim 1 in which the said at least one thyroid hormone compound or said thyroid hormone-like compound is in chemically pure form.

5. A composition according to claim 1 in which the pharmacologically acceptable base is selected from oil in water emulsions, sprays, liposomes and solutions.

6. A composition according to claim 1, in which the said at least one thyroid hormone compound or said thyroid hormone-like compound is at least partially dissolved in a solvent.

7. A composition according to claim 6 in which the solvent is an organic solvent.

8. A composition according to claim 7 in which the organic solvent is selected from alcohol and alcohol and water solutions.

9. A composition according to claim 8 in which the organic solvent is selected from isopropanol, isopropanol and water, ethanol, and ethanol and water solutions.

10. A composition according to claim 1, wherein said skin condition is selected from the group consisting of stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier'"'"'s disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, glucocorticoid induced atrophy, chloracne, pityriasis, and skin scarring.

11. A composition according to claim 1, further comprising at least one compound selected from the group consisting of a Vitamin D analogue, a glucocorticoid and a retinoid acid receptor binding compound.

12. A unit dose package containing a single dose of a composition according to claim 1.

13. A method of improving the skin condition of a subject, the method comprising the steps of:

providing a composition in accordance with claim 1; and

applying the said composition to the skin of the subject.

14. The method according to claim 13, in which said skin condition is selected from the group consisting of stria, cellulite, roughened skin, actinic skin damage, intrinsically aged skin, photodamaged skin, lichen planus, ichthyosis, acne, psoriasis, wrinkled skin, Dernier'"'"'s disease, eczema, atopic dermatitis, seborrhoeic dermatitis scleroderma, collagen deficient skin, glucocorticoid induced atrophy, chloracne, pityriasis, and skin scarring.

15. A method according to claim 13 in which the composition is applied from twice a day to every three days.

16. A composition according to claim 1, comprising less than or equal to about 50 mg/100 ml of thyroid hormone compound or thyroid hormone-like compound.

17. A composition according to claim 16 comprising less than or equal to about 20 mg/100 ml of thyroid hormone compound or thyroid hormone-like compound.

18. The skin treatment composition of claim 1, wherein said composition affects an improvement in the skin'"'"'s condition without resulting in systemic metabolism of the compound.

19. The skin treatment composition of claim 1, wherein a medically or cosmetically sufficient amount of thyroid hormone compound or thyroid hormone-like compound enters the skin but in which substantially no thyroid hormone compound or thyroid hormone-like compound subsequently has a serum concentration which is physiologically adverse after topical application of the compound.

20. The skin treatment composition of claim 1, further comprising an additional ingredient selected from the group consisting of medicinal herbs, butylated hydroxytoluene, butylated hydroxyanisole, para-aminobenzoic acid, Tinuvin P, and combinations thereof.

21. The skin treatment composition of claim 20, wherein said medicinal herbs are selected from the group consisting of Guto Kola, Cola nitada, Khella, cola nut, Camellia Suiensis, Guavana, clove, coffee, and combinations thereof.

23. A method according to claim 16 in which the gene to modulated is selected from genes encoding keratin 1, keratin 10, TGF beta-2, TGF-alpha, TGF beta-1, SCCE, Transglutaminase K, Keratin growth factor (KGF), procollagen 1A1, procollagen 3A-1, keratin 16, connective tissue growth factor CTGF, CRABP-II.

22. A method of modulating the expression of genes in the skin, the method comprising applying a composition comprising at least one thyroid hormone compound or said thyroid hormone-like compound together with a pharmacologically acceptable base to the skin, wherein said thyroid hormone compound or said thyroid hormone-like compound is a chemical entity which binds to TR-α

or TR-β

with a dissociation constant, K_d, lower than 1 μ

M.

24. A method of reducing subcutaneous fat deposits in a subject, the method comprising the steps of applying a composition to skin of the subject, said composition comprising at least one thyroid hormone compound or thyroid hormone-like compound together with a pharmacologically acceptable base, wherein said thyroid hormone compound or thyroid hormone-like compound is a chemical entity which binds to TR-α

or TR-β

with an equilibrium dissociation constant, K_d, lower than 1 μ

M, wherein

25. A method according to claim 24 in which the composition is applied to the skin from between twice a day to every three days.